Skip to main content
PMC home page
NeuroRx logoLink to NeuroRx
. 2012 Sep 5;3(2):217–224. doi: 10.1016/j.nurx.2006.01.008

Therapeutic interventions for tone abnormalities in cerebral palsy

Ann H Tilton 1,2,✉
PMCID: PMC3593441  PMID: 16554259

Summary

Cerebral palsy (CP) is a common cause of movement disorders in children. The upper motor neuron syndrome of CP leads to several types of muscle overactivity, including spasticity. Reduction of muscle overactivity may be an important treatment goal, to improve comfort, care, and active function and to prevent future musculoskeletal complications. After a comprehensive team evaluation, a treatment plan is generated. Treatments may include physical and occupational therapy, oral medications, botulinum toxin and/or phenol injections, intrathecal baclofen, selective dorsal rhizotomy, and orthopedic surgery. Successful and early prevention of contracture may reduce the need for later corrective surgery.

Key Words: Cerebral palsy, spasticity, botulinum toxin, intrathecal baclofen, selective dorsal rhizotomy, orthopedic surgery

References

  • 1.Surveillance of Cerebral Palsy in Europe (SCPE) Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Dev Med Child Neurol. 2000;42:816–824. doi: 10.1017/S0012162200001511. [DOI] [PubMed] [Google Scholar]
  • 2.Pharoah PO, Platt MJ, Cooke T. The changing epidemiology of cerebral palsy. Arch Dis Child Fetal Neonatal Ed. 1996;75:F169–F173. doi: 10.1136/fn.75.3.F169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Bax M, Goldstein M, Rosenbaum P, Leviton A, Paneth N, Dan B, Jacobsson B, Damiano D. Proposed definition and classification of cerebral palsy, April 2005. Dev Med Child Neurol. 2005;47:571–576. doi: 10.1017/S001216220500112X. [DOI] [PubMed] [Google Scholar]
  • 4.Nelson KB, Ellenberg JH. Epidemiology of cerebral palsy. Adv Neurol. 1978;19:421–435. [PubMed] [Google Scholar]
  • 5.Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW. Classification and definition of disorders causing hypertonia in childhood. Pediatrics. 2003;111:e89–e97. doi: 10.1542/peds.111.1.e89. [DOI] [PubMed] [Google Scholar]
  • 6.Mayer NH. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motor neuron lesion. In: Mayer NH, Simpson DM, editors. Spasticity: etiology, evaluation, management, and the role of botulinum toxin. New York: WE MOVE; 2002. pp. 1–15. [Google Scholar]
  • 7.Russman BS, Tilton A, Gormley ME. Cerebral palsy: a rational approach to a treatment protocol, and the role of botulinum toxin in treatment. Muscle Nerve Suppl. 1997;6:S181–S193. doi: 10.1002/(SICI)1097-4598(1997)6+<181::AID-MUS13>3.0.CO;2-9. [DOI] [PubMed] [Google Scholar]
  • 8.Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP, editors. Spasticity: disordered motor control. Chicago: Yearbook Medical; 1980. pp. 485–494. [Google Scholar]
  • 9.Mayer NH, Herman RM. Phenomenology of muscle overactivity in the upper motor neuron syndrome. In: Mayer NH, Pierson SH, editors. Muscle overactivity in the upper motor neuron syndrome: the role of oral medications, a focus on dantrolene sodium. New York: WE MOVE; 2004. pp. 1–25. [Google Scholar]
  • 10.Bohannon RW, Smith MB. Interrater reliablity of a modified Ashworth scale of muscle spasticity. Phys Ther. 1986;67:206–207. doi: 10.1093/ptj/67.2.206. [DOI] [PubMed] [Google Scholar]
  • 11.Reimers J. Clinically based decision-making for surgery. In: Sussman MD, editor. The diplegic child evaluation and management. Rosemont, IL: American Academy of Orthopedic Surgeons; 1991. pp. 151–151. [Google Scholar]
  • 12.Benda W, McGibbon NH, Grant KL. Improvements in muscle symmetry in children with cerebral palsy after equine-assisted therapy (hippotherapy) J Altern Complement Med. 2003;9:817–825. doi: 10.1089/107555303771952163. [DOI] [PubMed] [Google Scholar]
  • 13.Dali C, Hansen FJ, Pedersen SA, Skov L, Hilden J, Bjomskov I, Strandberg C, Jette C, Ulla H, Herbst G, Ulla L. Threshold electrical stimulation (TES) in ambulant children with CP: a randomized double-blind placebo-controlled clinical trial. Dev Med Child Neurol. 2002;44:364–369. doi: 10.1111/j.1469-8749.2002.tb00830.x. [DOI] [PubMed] [Google Scholar]
  • 14.Hakkennes S, Keating JL. Constraint-induced movement therapy following stroke: a systematic review of randomised controlled trials. Aust J Physiother. 2005;51:221–231. doi: 10.1016/S0004-9514(05)70003-9. [DOI] [PubMed] [Google Scholar]
  • 15.Taub E, Ramey SL, DeLuca S, Echols K. Efficacy of constraint-induced movement therapy for children with cerebral palsy with asymmetric motor impairment. Pediatrics. 2004;113:305–312. doi: 10.1542/peds.113.2.305. [DOI] [PubMed] [Google Scholar]
  • 16.Damiano DL, Abel MF. Functional outcomes of strength training in spastic cerebral palsy. Arch Phys Med Rehabil. 1998;79:119–125. doi: 10.1016/S0003-9993(98)90287-8. [DOI] [PubMed] [Google Scholar]
  • 17.Dodd KJ, Taylor NF, Graham HK. A randomized clinical trial of strength training in young people with cerebral palsy. Dev Med Child Neurol. 2003;45:652–657. doi: 10.1111/j.1469-8749.2003.tb00866.x. [DOI] [PubMed] [Google Scholar]
  • 18.McBurney H, Taylor NF, Dodd KJ, Graham HK. A qualitative analysis of the benefits of strength training for young people with cerebral palsy. Dev Med Child Neurol. 2003;45:658–663. doi: 10.1111/j.1469-8749.2003.tb00867.x. [DOI] [PubMed] [Google Scholar]
  • 19.Carlson WE, Vaughan CL, Damiano DL, Abel MF. Orthotic management of gait in spastic diplegia. Am J Phys Med Rehabil. 1997;76:219–225. doi: 10.1097/00002060-199705000-00012. [DOI] [PubMed] [Google Scholar]
  • 20.Wilson H, Haideri N, Song K, Telford D. Ankle-foot orthoses for preambulatory children with spastic diplegia. J Pediatr Orthop. 1997;17:370–376. doi: 10.1097/00004694-199705000-00019. [DOI] [PubMed] [Google Scholar]
  • 21.Corry IS, Cosgrove AP, Duffy CM, McNeill S, Taylor TC, Graham HK. Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. J Pediatr Orthop. 1998;18:304–311. doi: 10.1097/00004694-199805000-00006. [DOI] [PubMed] [Google Scholar]
  • 22.Flett PJ, Stern LM, Waddy H, Connell TM, Seeger JD, Gibson SK. Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy. J Paediatr Child Health. 1999;35:71–77. doi: 10.1046/j.1440-1754.1999.00330.x. [DOI] [PubMed] [Google Scholar]
  • 23.Bottos M, Benedetti MG, Salucci P, Gasparroni V, Giannini S. Botulinum toxin with and without casting in ambulant children with spastic diplegia: a clinical and functional assessment. Dev Med Child Neurol. 2003;45:758–762. doi: 10.1111/j.1469-8749.2003.tb00885.x. [DOI] [PubMed] [Google Scholar]
  • 24.Kay RM, Rethlefsen SA, Fem-Buneo A, Wren TA, Skaggs DL. Botulinum toxin as an adjunct to serial casting treatment in children with cerebral palsy. J Bone Joint Surg Am. 2004;86A:2377–2384. doi: 10.2106/00004623-200411000-00003. [DOI] [PubMed] [Google Scholar]
  • 25.Ackman JD, Russman BS, Thomas SS, Buckon CE, Sussman MD, Masso P, et al. Comparing botulinum toxin A with casting for treatment of dynamic equinus in children with cerebral palsy. Dev Med Child Neurol. 2005;47:620–627. [PubMed] [Google Scholar]
  • 26.Gracies JM, Nance P, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments. Muscle Nerve Suppl. 1997;6:S92–S120. doi: 10.1002/(SICI)1097-4598(1997)6+<92::AID-MUS7>3.0.CO;2-E. [DOI] [PubMed] [Google Scholar]
  • 27.Mathew A, Mathew MC, Thomas M, Antonisamy B. The efficacy of diazepam in enhancing motor function in children with spastic cerebral palsy. J Trop Pediatr. 2005;51:109–113. doi: 10.1093/tropej/fmh095. [DOI] [PubMed] [Google Scholar]
  • 28.Holt KS. The use of diazepam in childhood cerebral palsy: report of a small study including electromyographic observations.Ann Phys Med [Suppl]:16-24, 1964. [DOI] [PubMed]
  • 29.Engle HA. The effect of diazepam (Valium) in children with cerebral palsy: a double-blind study. Dev Med Child Neurol. 1966;8:661–667. doi: 10.1111/j.1469-8749.1966.tb01824.x. [DOI] [PubMed] [Google Scholar]
  • 30.Dahlin M, Knutsson E, Nergardh A. Treatment of spasticity in children with low dose benzodiazepine. J Neurol Sci. 1993;117:54–60. doi: 10.1016/0022-510X(93)90154-Q. [DOI] [PubMed] [Google Scholar]
  • 31.Milla PJ, Jackson AD. A controlled trial of baclofen in children with cerebral palsy. J Int Med Res. 1977;5:398–404. doi: 10.1177/030006057300100203. [DOI] [PubMed] [Google Scholar]
  • 32.Brin IL, Kurenkov AL, Gotlib VI. [The use of sirdalud in cerebral palsy in children] Zh Nevrol Psikhiatr Im S S Korsakova. 1999;99:30–33. [PubMed] [Google Scholar]
  • 33.Joynt RL, Leonard JA. Dantrolene sodium suspension in treatment of spastic cerebral palsy. Dev Med Child Neurol. 1980;22:755–767. doi: 10.1111/j.1469-8749.1980.tb03742.x. [DOI] [PubMed] [Google Scholar]
  • 34.Nogen AG. Medical treatment for spasticity in children with cerebral palsy. Childs Brain. 1976;2:304–308. doi: 10.1159/000119626. [DOI] [PubMed] [Google Scholar]
  • 35.Chyatte SB, Birdsong JH, Bergman BA. The effects of dantrolene sodium on spasticity and motor performance in hemiplegia. South Med J. 1971;64:180–185. doi: 10.1097/00007611-197102000-00011. [DOI] [PubMed] [Google Scholar]
  • 36.Brin MF, Aoki KR. Botulinum toxin type A: pharmacology. In: Mayer NH, Simpson DM, editors. Spasticity: etiology, evaluation, management, and the role of botulinum toxin. New York: WE MOVE; 2002. pp. 110–124. [Google Scholar]
  • 37.WE MOVE. 2005 Management of spasticity with botulinum toxin type A (BOTOX®) [Online], 2005. Accessed January 4, 2006.
  • 38.Speth LA, Leffers P, Janssen-Potten YJ, Vles JS. Botulinum toxin A and upper limb functional skills in hemiparetic cerebral palsy: a randomized trial in children receiving intensive therapy. Dev Med Child Neurol. 2005;47:468–473. doi: 10.1017/S0012162205000903. [DOI] [PubMed] [Google Scholar]
  • 39.Steenbeek D, Meester-Delver A, Becher JG, Lankhorst GJ. The effect of botulinum toxin type A treatment of the lower extremity on the level of functional abilities in children with cerebral palsy: evaluation with goal attainment scaling. Clin Rehabil. 2005;19:274–282. doi: 10.1191/0269215505cr859oa. [DOI] [PubMed] [Google Scholar]
  • 40.Wallen MA, O’Flaherty SJ, Waugh MC. Functional outcomes of intramuscular botulinum toxin type A in the upper limbs of children with cerebral palsy: a phase II trial. Arch Phys Med Rehabil. 2004;85:192–200. doi: 10.1016/j.apmr.2003.05.008. [DOI] [PubMed] [Google Scholar]
  • 41.Baker R, Jasinski M, Iag-Tymecka I, Michalowska-Mrozek J, Bonikowski M, Can- L, MacLean J, Lin JP, Lynch B, Theologis T, Wendorff J, Eunson P, Cosgrove A. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol. 2002;44:666–675. doi: 10.1111/j.1469-8749.2002.tb00268.x. [DOI] [PubMed] [Google Scholar]
  • 42.Fehlings D, Rang M, Glazier J, Steele C. An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr. 2000;137:331–337. doi: 10.1067/mpd.2000.108393. [DOI] [PubMed] [Google Scholar]
  • 43.Sutherland DH, Kaufman KR, Wyatt MP, Chambers HG, Mubarak SJ. Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture. 1999;10:1–9. doi: 10.1016/S0966-6362(99)00012-0. [DOI] [PubMed] [Google Scholar]
  • 44.Cony IS, Cosgrove AP, Walsh EG, McClean D, Graham HK. Botulinum toxin A in the hemiplegic upper limb: a double-blind trial. Dev Med Child Neurol. 1997;39:185–193. doi: 10.1111/j.1469-8749.1997.tb07408.x. [DOI] [PubMed] [Google Scholar]
  • 45.Gracies JM, Elovic E, McGuire J, Simpson DM. Traditional pharmacologic treatments for spasticity. Part I: local treatments. In: Mayer NH, Simpson DM, editors. Spasticity: etiology, evaluation, management, and the role of botulinum toxin. New York: WE MOVE; 2005. pp. 44–64. [Google Scholar]
  • 46.Wong AM, Chen CL, Chen CP, Chou SW, Chung CY, Chen MJ. Clinical effects of botulinum toxin A and phenol block on gait in children with cerebral palsy. Am J Phys Med Rehabil. 2004;83:284–291. doi: 10.1097/01.PHM.0000118038.02326.CA. [DOI] [PubMed] [Google Scholar]
  • 47.Gooch JL, Patton CP. Combining botulinum toxin and phenol to manage spasticity in children. Arch Phys Med Rehabil. 2004;85:1121–1124. doi: 10.1016/j.apmr.2003.09.032. [DOI] [PubMed] [Google Scholar]
  • 48.Albright AL, Barron WB, Fasick MP, Polinko P, Janosky J. Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA. 1993;270:2475–2477. doi: 10.1001/jama.1993.03510200081036. [DOI] [PubMed] [Google Scholar]
  • 49.Rawlins PK. Intrathecal baclofen therapy over 10 years. J Neurosci Nurs. 2004;36:322–327. doi: 10.1097/01376517-200412000-00005. [DOI] [PubMed] [Google Scholar]
  • 50.Gilmartin R, Bruce D, Stons BB, Abbott R, Krach L, Ward J, Bloom K, Brooks WH, Johnson DL, Madsen JR, McLaughlin JF, Nadell J. Intrathecal baclofen for management of spastic cerebral palsy: multicenter trial. J Child Neurol. 2000;15:71–77. doi: 10.1177/088307380001500201. [DOI] [PubMed] [Google Scholar]
  • 51.Van SP, Nuttin B, Lagae L, Schrijvers E, Borghgraef C, Feys P. Intrathecal baclofen for intractable cerebral spasticity: a prospective placebo-controlled, double-blind study. Neurosurgery. 2000;46:603–609. doi: 10.1097/00006123-200003000-00017. [DOI] [PubMed] [Google Scholar]
  • 52.Gerszten PC, Albright AL, Barry MJ. Effect on ambulation of continuous intrathecal baclofen infusion. Pediatr Neurosurg. 1997;27:40–44. doi: 10.1159/000121223. [DOI] [PubMed] [Google Scholar]
  • 53.Gerszten PC, Albright AL, Johnstone GF. Intrathecal baclofen infusion and subsequent orthopedic surgery in patients with spastic cerebral palsy. J Neurosurg. 1998;88:1009–1013. doi: 10.3171/jns.1998.88.6.1009. [DOI] [PubMed] [Google Scholar]
  • 54.Murphy NA, Irwin MC, Hoff C. Intrathecal baclofen therapy in children with cerebral palsy: efficacy and complications. Arch Phys Med Rehabil. 2002;83:1721–1725. doi: 10.1053/apmr.2002.36068. [DOI] [PubMed] [Google Scholar]
  • 55.Zuckerbraun NS, Ferson SS, Albright AL, Vogeley E. Intrathecal baclofen withdrawal: emergent recognition and management. Pediatr Emerg Care. 2004;20:759–764. doi: 10.1097/01.pec.0000144919.08619.95. [DOI] [PubMed] [Google Scholar]
  • 56.Darbari FP, Melvin JJ, Piatt JH, Adirim TA, Kothare SV. Intrathecal baclofen overdose followed by withdrawal: clinical and EEG features. Pediatr Neurol. 2005;33:373–377. doi: 10.1016/j.pediatrneurol.2005.05.017. [DOI] [PubMed] [Google Scholar]
  • 57.Steinbok P. Outcomes after selective dorsal rhizotomy for spastic cerebral palsy. Childs Nerv Syst. 2001;17:1–18. doi: 10.1007/PL00013722. [DOI] [PubMed] [Google Scholar]
  • 58.van Schie PE, Vermeiden RJ, van Ouwerkerk WJ, Kwakkel G, Becher JG. Selective dorsal rhizotomy in cerebral palsy to improve functional abilities: evaluation of criteria for selection. Childs Nerv Syst. 2005;21:451–457. doi: 10.1007/s00381-004-1105-1. [DOI] [PubMed] [Google Scholar]
  • 59.Galarza M, Fowler EG, Chipps L, Padden TM, Lazareff JA. Functional assessment of children with cerebral palsy following limited (L4-S1) selective posterior rhizotomy-a preliminary report. Acta Neurochir (Wien) 2001;143:865–872. doi: 10.1007/s007010170016. [DOI] [PubMed] [Google Scholar]
  • 60.Wright FV, Sheil EM, Drake JM, Wedge JH, Naumann S. Evaluation of selective dorsal rhizotomy for the reduction of spasticity in cerebral palsy: a randomized controlled trial. Dev Med Child Neurol. 1998;40:239–247. doi: 10.1111/j.1469-8749.1998.tb15456.x. [DOI] [PubMed] [Google Scholar]
  • 61.Steinbok P, Reiner AM, Beauchamp R, Armstrong RW. Cochrane DD, Kestle J. A randomized clinical trial to compare selective posterior rhizotomy plus physiotherapy with physiotherapy alone in children with spastic diplegic cerebral palsy. Dev Med Child Neurol. 1997;39:178–184. doi: 10.1111/j.1469-8749.1997.tb07407.x. [DOI] [PubMed] [Google Scholar]
  • 62.McLaughlin JF, Bjomson KF, Astley SJ, Graubert C, Hays RM, Roberts TS, Price R, Temkin N. Selective dorsal rhizotomy: efficacy and safety in an investigator-masked randomized clinical trial. Dev Med Child Neurol. 1998;40:220–232. doi: 10.1111/j.1469-8749.1998.tb15454.x. [DOI] [PubMed] [Google Scholar]
  • 63.Engsberg JR, Ross SA, Park TS. Changes in ankle spasticity and strength following selective dorsal rhizotomy and physical therapy for spastic cerebral palsy. J Neurosurg. 1999;91:727–732. doi: 10.3171/jns.1999.91.5.0727. [DOI] [PubMed] [Google Scholar]
  • 64.Johnson MB, Goldstein L, Thomas SS, Piatt J, Aiona M, Sussman M. Spinal deformity after selective dorsal rhizotomy in ambulatory patients with cerebral palsy. J Pediatr Orthop. 2004;24:529–536. doi: 10.1097/01241398-200409000-00013. [DOI] [PubMed] [Google Scholar]
  • 65.Steinbok P, Hicdonmez T, Sawatzky B, Beauchamp R, Wickenheiser D. Spinal deformities after selective dorsal rhizotomy for spastic cerebral palsy. J Neurosurg. 2005;102:363–373. doi: 10.3171/jns.2005.102.2.0363. [DOI] [PubMed] [Google Scholar]
  • 66.Chicoine MR, Park TS, Kaufman BA. Selective dorsal rhizotomy and rates of orthopedic surgery in children with spastic cerebral palsy. J Neurosurg. 1997;86:34–39. doi: 10.3171/jns.1997.86.1.0034. [DOI] [PubMed] [Google Scholar]
  • 67.Hagglund G, Andersson S, Duppe H, Pedertsen HL, Nordmark E, Westbom L. Prevention of severe contractures might replace multilevel surgery in cerebral palsy: results of a population-based health care programme and new techniques to reduce spasticity. J Pediatr Orthop B. 2005;14:269–273. doi: 10.1097/01202412-200507000-00007. [DOI] [PubMed] [Google Scholar]

Articles from NeuroRx are provided here courtesy of Am. Soc. for Experimental NeuroTherapeutics

RESOURCES